Everest Medicines (STU:6HN) EPS (Basic) : €-0.42 (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Everest Medicines EPS (Basic)?

Everest Medicines's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was €-0.17. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.42.

Everest Medicines's EPS (Diluted) for the six months ended in Dec. 2024 was €-0.17. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.42.

Everest Medicines's EPS without NRI for the six months ended in Dec. 2024 was €-0.17. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.28.

During the past 3 years, the average EPS without NRI Growth Rate was 18.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Everest Medicines's highest 3-Year average EPS without NRI Growth Rate was 34.70% per year. The lowest was -101.00% per year. And the median was -30.30% per year.

Everest Medicines EPS (Basic) Historical Data

The historical data trend for Everest Medicines's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines EPS (Basic) Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-8.33

-0.48

-0.11

-0.35

-0.43

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	Get a 7-Day Free Trial							0.19	-0.18	-0.17	-0.25	-0.17

Everest Medicines EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Everest Medicines's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-136.596	-	0)	/	320.918
	=	-0.43

Everest Medicines's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-53.643	-	0)	/	321.094
	=	-0.17

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.42

Everest Medicines (STU:6HN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Everest Medicines EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Everest Medicines's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (STU:6HN) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

01952:Hong Kong 6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Everest Medicines Headlines

No Headlines